GLP1R and metabolic dysfunction-associated steatotic liver disease: In parallel, increases in level of T-β MCA, an intestinal FXR antagonist, ameliorates NAFLD through increased BAs synthesis [135–137], and GLP-1 secretion decreases via the activation of intestinal FXR [138].